Syngene International has announced the acquisition of its first biologics facility in the United States.
The site, which includes multiple monoclonal antibody (mAbs) manufacturing lines, was purchased from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc.
This acquisition, made through Syngene USA Inc., a wholly owned subsidiary, strengthens the company's biologics presence and enhances its ability to serve clients across human and animal health sectors. With this addition, Syngene's total single-use bioreactor capacity will reach 50,000 litres, supporting large molecule discovery, development, and manufacturing.
The site will complement Syngene’s four existing development and manufacturing facilities in India and North America, providing end-to-end services from cell line development and process optimisation to clinical and commercial supply.
The investment reflects Syngene's commitment to the US market, supporting local job creation, economic activity, and the expansion of domestic biologics manufacturing. By increasing production capacity, the facility will contribute to pharmaceutical innovation and supply chain resilience while strengthening economic ties between India and the United States.
The new facility will enable Syngene to meet growing demand from global pharmaceutical and biotech companies, providing flexible manufacturing options across multiple geographic locations. It is expected to benefit clients in the animal health sector seeking US Department of Agriculture (USDA) approvals.
The investment will also align with Syngene’s process development activities in India, allowing manufacturing to take place in the US as needed.
The acquisition is valued at approximately US$50 million, including US$36.5 million for the facility purchase and additional costs to make the site operational. The transaction is expected to be completed by March 2025, subject to regulatory approvals and customary closing conditions.
The upgraded Baltimore facility, strategically located near key biotech hubs in the Northeast US, is scheduled to be operational for client projects in the second half of 2025.